Glycaemic control + weight
CagriSema in type 2 diabetes
REIMAGINE 2 enrolled 2,713 participants and found greater HbA1c reduction with CagriSema 2.4/2.4 mg versus semaglutide 2.4 mg; GI disorders were the most.
Exact-combination evidence
Phase III combination evidence
REIMAGINE 2 enrolled 2,713 participants and found greater HbA1c reduction with CagriSema 2.4/2.4 mg versus semaglutide 2.4 mg; GI disorders were the most common adverse events. Integrity note: Do not infer that cagrilintide alone matches the combination's efficacy.
Human combination evidence
Yes — REIMAGINE 1/2 and REDEFINE 2
Combination safety
Yes